Chondroitin slows progression and relieves symptoms of knee osteoarthritis

Jan 29, 2009

Osteoarthritis (OA) causes disability and is a major public health problem. A new study examined the effect of chondroitins 4 and 6 sulfate (CS) on OA progression and symptoms. CS, unlike other chondroitin sulfate products sold as dietary supplements in the U.S., has been approved as a prescription symptomatic slow acting drug for OA in many European countries. The study was published in the February issue of Arthritis & Rheumatism.

Led by Andre Kahan of the University of Paris Descartes in Paris, the randomized, double-blind, placebo-controlled study involved 622 patients with OA from France, Belgium, Switzerland, Austria and the U.S. Patients had knee X-rays at the time of enrollment and at 12, 18 and 24 months. The X-rays were evaluated for joint space loss and patients were also assessed for OA symptoms and pain.

The results showed that "long-term administration of CS over 2 years can prevent joint structure degradation in patients with knee OA," the authors state. Joint space loss was significantly reduced in the CS group, fewer patients had progression of joint space width, and CS reduced pain in those taking it compared to the placebo group. CS was well-tolerated and there were no significant differences in the frequency of adverse events between the two groups.

The study showed that there was faster improvement regarding pain during the first year in the CS group compared to the placebo group. This may be due to the fact that all of the patients had pain symptoms, so the effect of CS was more noticeable early on. Since those who took a placebo also had decreased pain in the first year, it may also be due to the natural course of the disease. The authors note that the study involved CS, which is used as a prescription drug and that the results cannot be generalized to other chondroitin sulfate products or compounds, such as those available in the form of dietary supplements.

The decrease in joint space loss shown in this and another recent study involving 300 patients, suggests better outcomes for OA patients, according to the authors. They conclude: "Further studies with longer followup and different outcome criteria are warranted to assess whether the beneficial structural changes associated with CS demonstrated in our study are predictive of improvement in the long-term clinical progression of OA."

Journal: www3.interscience.wiley.com/journal/76509746/home

Source: Wiley

Explore further: App for headache sufferers shows success

add to favorites email to friend print save as pdf

Related Stories

Huge waves measured for first time in Arctic Ocean

6 hours ago

As the climate warms and sea ice retreats, the North is changing. An ice-covered expanse now has a season of increasingly open water which is predicted to extend across the whole Arctic Ocean before the middle ...

Underwater elephants

6 hours ago

In the high-tech world of science, researchers sometimes need to get back to basics. UC Santa Barbara's Douglas McCauley did just that to study the impacts of the bumphead parrotfish (Bolbometopon muricatum) on cor ...

Recommended for you

Reducing kidney injury using a quality improvement method

4 minutes ago

Using quality improvement measures in eight of the 10 hospitals in the Northern New England Cardiovascular Disease Study Group, researchers have found a way to reduce kidney injury in patients undergoing a procedure with ...

App for headache sufferers shows success

12 hours ago

A unique app that helps headache sufferers to record the severity and regularity of their pain is being used as part of a Griffith research study.

West African airline suspends flights amid Ebola (Update)

17 hours ago

(AP)—Police officers deployed to Liberia's international airport to ensure passengers are screened for Ebola symptoms as a major regional airline announced Tuesday it was suspending flights to the cities hardest hit by ...

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

VOR
not rated yet Jan 30, 2009
"CS, unlike other chondroitin sulfate products sold as dietary supplements in the U.S., has been approved as a prescription symptomatic slow acting drug for OA in many European countries" .... I'm confused by the wording 'CS, unlike other chondroitin sufate products'... this implies it is different and unique, but I dont think thats what they mean to say.. very confusing! is it unique chemically or only unique in that its approved? anyone know? I think its the latter but its written so poorly I cant be sure.
VOR
not rated yet Feb 01, 2009
this helps clarify: http://www.nutrai...on-Study